scholarly journals Development of theranostic dual-layered Au-liposome for effective tumor targeting and photothermal therapy

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Miyeon Jeon ◽  
Gaeun Kim ◽  
Wooseung Lee ◽  
Seungki Baek ◽  
Han Na Jung ◽  
...  
Keyword(s):  
In Vivo Imaging ◽  
Photothermal Therapy ◽  
Tumor Targeting ◽  
Therapeutic Strategy ◽  
Tumor Growth Inhibition ◽  
Positron Emission ◽  
Anti Cancer ◽  
Good Biocompatibility ◽  
Targeting Ability

Abstract Background Photothermal therapy (PTT) is an emerging anti-cancer therapeutic strategy that generates hyperthermia to ablate cancer cells under laser irradiation. Gold (Au) coated liposome (AL) was reported as an effective PTT agent with good biocompatibility and excretory property. However, exposed Au components on liposomes can cause instability in vivo and difficulty in further functionalization. Results Herein, we developed a theranostic dual-layered nanomaterial by adding liposomal layer to AL (LAL), followed by attaching polyethylene glycol (PEG) and radiolabeling. Functionalization with PEG improves the in vivo stability of LAL, and radioisotope labeling enables in vivo imaging of LAL. Functionalized LAL is stable in physiological conditions, and 64Cu labeled LAL (64Cu-LAL) shows a sufficient blood circulation property and an effective tumor targeting ability of 16.4%ID g−1 from in vivo positron emission tomography (PET) imaging. Also, intravenously injected LAL shows higher tumor targeting, temperature elevation in vivo, and better PTT effect in orthotopic breast cancer mouse model compared to AL. The tumor growth inhibition rate of LAL was 3.9-fold higher than AL. Conclusion Based on these high stability, in vivo imaging ability, and tumor targeting efficiency, LAL could be a promising theranostic PTT agent. Graphic Abstract

Intravenous, Intraperitoneal, and Subcutaneous Routes of Administering 64Cu-DOTA-HB22.7 Display Equivalent Tumor Targeting Ability.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2359-2359
Author(s):  
Shiloh M. Martin ◽  
Robert T. O’Donnell ◽  
Hayes McKnight ◽  
Julie L. Sutcliff ◽  
Joseph M. Tuscano
Keyword(s):  
Nude Mice ◽  
Tumor Targeting ◽  
Emission Tomography ◽  
New Agents ◽  
Routes Of Administration ◽  
Positron Emission ◽  
Specific Tumor ◽  
Human Lymphoma ◽  
Targeting Ability

Abstract BACKGROUND: Chemotherapy for Non-Hodgkin’s Lymphoma (NHL) is initially effective, but often limited by toxicity and resistance. New agents for the treatment of NHL are needed. HB22.7 is a monoclonal antibody that binds CD22 and has previously been shown to reduce human lymphoma xenograft volume in nude mice. OBJECTIVES: (1) Develop a 64Cu-DOTA-HB22.7 antibody, for in vivo imaging and potential therapy of NHL. (2) Determine if tumor targeting of 64Cu-DOTA-HB22.7 is equivalent between intravenous (IV), intraperitoneal (IP), and subcutaneous (SQ) routes of administration. METHODS: DOTA-HB22.7’s ability to bind CD22+ cells was assessed by flow cytometry. 64Cu-DOTA-HB22.7 was injected IV, IP, or SQ into xenograft-bearing nude mice and tumor targeting assessed by positron emission tomography (PET) and biodistribution assay. Pharmacokinetics were determined by measuring radioactivity of blood samples. Serum was analyzed by radio-TLC. RESULTS: DOTA conjugation does not affect HB22.7’s ability to bind CD22. 64Cu-DOTA-HB22.7 demonstrates specific tumor targeting at 24 and 48 hrs. Targeting is equivalent regardless of route of administration. Pharmacokinetics demonstrate that 64Cu-DOTA-HB22.7 can access the bloodstream (and thus, target tumor) in IP or SQ injections. By 48 hrs, blood 64Cu levels are (a) equivalent, regardless of injection route and (b) below peak levels, indicating clearance from the circulation. Serum analysis shows that right-shifted TLC peaks, possibly 64Cu-DOTA-HB22.7 metabolites, are present only in the IV injected group at 48 hrs. CONCLUSION: These findings establish 64Cu-DOTA-HB22.7 as an NHL-specific imaging agent and indicate its potential for use in radioimmunotherapy. These findings provide evidence that more accessible routes of administration can achieve equivalent targeting results, and may lead to more efficient and accurate administration of antibody-based therapeutics in mice.

scholarly journals In vivo Imaging-Guided Nanoplatform for Tumor Targeting Delivery and Combined Chemo-, Gene- and Photothermal Therapy

Theranostics ◽  
2018 ◽  
Vol 8 (20) ◽  
pp. 5662-5675 ◽  
Author(s):  
Cheng Li ◽  
Xiao-Quan Yang ◽  
Ming-Zhen Zhang ◽  
Yuan-Yang Song ◽  
Kai Cheng ◽  
...  
Keyword(s):  
In Vivo Imaging ◽  
Photothermal Therapy ◽  
Tumor Targeting ◽  
Targeting Delivery

scholarly journals AIE nanoparticles camouflaged with tumor cell-derived exosomes for NIR-II imaging-guided photothermal therapy

2021 ◽  
Author(s):  
Yirun Li ◽  
Xiaoxiao Fan ◽  
Yuanyuan Li ◽  
Runze Chen ◽  
Huwei Ni ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Photothermal Therapy ◽  
Tumor Targeting ◽  
Near Infrared ◽  
Specific Targeting ◽  
Specific Tumor ◽  
Targeting Ability ◽  
Targeting Strategy

Nanoparticles (NPs) assisted photothermal therapy (PTT) is a promising cancer treatment modality and has attracted the attention of the scientific mainstream. However, developing NPs that exhibit efficient optical properties and specific tumor targeting capability simultaneously is difficult. Herein, we develop hybrid nanovesicles consisting of tumor cell-derived exosomes (EXO) and organic aggregation-induced emission (AIE) nanoparticles (TT3-oCB NP@EXOs) with enhanced second near-infrared (NIR-II, 900-1700 nm) fluorescence property and PTT functionality. Compared with TT3-oCB NPs, TT3-oCB NP@EXOs exhibit excellent biocompatibility, specific targeting ability in vitro, homing to homologous tumors in vivo, and prolonged circulation time. Furthermore, TT3-oCB NP@EXOs were utilized as biomimetic NPs for NIR-II fluorescence imaging-guided PTT of tumors, due to their high and stable photothermal conversion capacity under 808 nm irradiation. Therefore, the tumor cell-derived EXO/AIE NP hybrid nanovesicles may provide an alternative artificial targeting strategy for improving tumor diagnosis and PTT.

Multiple-Armed Tetrahedral DNA Nanostructures for Tumor-Targeting, Dual-Modality in Vivo Imaging

2016 ◽  
Vol 8 (7) ◽  
pp. 4378-4384 ◽  
Author(s):  
Dawei Jiang ◽  
Yanhong Sun ◽  
Jiang Li ◽  
Qian Li ◽  
Min Lv ◽  
...  
Keyword(s):  
In Vivo Imaging ◽  
Tumor Targeting ◽  
Dna Nanostructures ◽  
Dual Modality

scholarly journals Correction to: In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Johannes Notni ◽  
Florian T. Gassert ◽  
Katja Steiger ◽  
Peter Sommer ◽  
Wilko Weichert ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Positron Emission Tomography ◽  
In Vivo Imaging ◽  
Emission Tomography ◽  
Early Stages ◽  
Positron Emission ◽  
Α5β1 Integrin

Following publication of the original article [1], the authors have reported an error in the ‘Histopathology’ (under ‘Materials and methods’) section of the article that compromises the reproducibility of the paper.

scholarly journals 11C- and 18F-Radiotracers for In Vivo Imaging of the Dopamine System: Past, Present and Future

Biomedicines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 108
Author(s):  
Michael R. Kilbourn
Keyword(s):  
Pet Imaging ◽  
In Vivo Imaging ◽  
Dopamine Synthesis ◽  
Dopamine System ◽  
Synaptic Release ◽  
Positron Emission ◽  
The Central Nervous System ◽  
Pet Radiotracers ◽  
Selection Of

The applications of positron emission tomography (PET) imaging to study brain biochemistry, and in particular the aspects of dopamine neurotransmission, have grown significantly over the 40 years since the first successful in vivo imaging studies in humans. In vivo PET imaging of dopaminergic functions of the central nervous system (CNS) including dopamine synthesis, vesicular storage, synaptic release and receptor binding, and reuptake processes, are now routinely used for studies in neurology, psychiatry, drug abuse and addiction, and drug development. Underlying these advances in PET imaging has been the development of the unique radiotracers labeled with positron-emitting radionuclides such as carbon-11 and fluorine-18. This review focuses on a selection of the more accepted and utilized PET radiotracers currently available, with a look at their past, present and future.

scholarly journals In Vivo Imaging of Insulin Receptors in Monkeys Using 18F-Labeled Insulin and Positron Emission Tomography

Diabetes ◽  
1992 ◽  
Vol 41 (7) ◽  
pp. 855-860 ◽  
Author(s):  
R. C. Eastman ◽  
R. E. Carson ◽  
K. A. Jacobson ◽  
Y. Shai ◽  
M. A. Channing ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
In Vivo Imaging ◽  
Insulin Receptors ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Designer Oncolytic Adenovirus: Coming of Age

Cancers ◽  
2018 ◽  
Vol 10 (6) ◽  
pp. 201 ◽  
Author(s):  
Alexander Baker ◽  
Carmen Aguirre-Hernández ◽  
Gunnel Halldén ◽  
Alan Parker
Keyword(s):  
Checkpoint Inhibitors ◽  
Coming Of Age ◽  
Oncolytic Adenovirus ◽  
Detailed Knowledge ◽  
Immunomodulatory Agents ◽  
Double Stranded Dna ◽  
Wide Range ◽  
Anti Cancer ◽  
Targeting Ability

The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virotherapy, especially in combination with immune-checkpoint inhibitors, the quest continues for a virus capable of specific tumour cell killing via systemic administration. One candidate is oncolytic adenovirus (Ad); it’s double stranded DNA genome is easily manipulated and a wide range of strategies and technologies have been employed to empower the vector with improved pharmacokinetics and tumour targeting ability. As well characterised clinical and experimental agents, we have detailed knowledge of adenoviruses’ mechanisms of pathogenicity, supported by detailed virological studies and in vivo interactions. In this review we highlight the strides made in the engineering of bespoke adenoviral vectors to specifically infect, replicate within, and destroy tumour cells. We discuss how mutations in genes regulating adenoviral replication after cell entry can be used to restrict replication to the tumour, and summarise how detailed knowledge of viral capsid interactions enable rational modification to eliminate native tropisms, and simultaneously promote active uptake by cancerous tissues. We argue that these designer-viruses, exploiting the viruses natural mechanisms and regulated at every level of replication, represent the ideal platforms for local overexpression of therapeutic transgenes such as immunomodulatory agents. Where T-Vec has paved the way, Ad-based vectors now follow. The era of designer oncolytic virotherapies looks decidedly as though it will soon become a reality.

scholarly journals In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography

Oncotarget ◽  
2015 ◽  
Vol 6 (35) ◽  
pp. 37486-37499 ◽  
Author(s):  
Carsten H. Nielsen ◽  
Mette M. Jensen ◽  
Lotte K. Kristensen ◽  
Anna Dahlman ◽  
Camilla Fröhlich ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
In Vivo Imaging ◽  
Therapy Response ◽  
Emission Tomography ◽  
Positron Emission ◽  
Antibody Mixture
Sign in / Sign up

Export Citation Format

Share Document